UPDATE 1-Geron's blood disorder drug gets FDA advisers' backing [Yahoo! Finance]
Geron Corporation (GERN)
Last geron corporation earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
geron.com/investors
Company Research
Source: Yahoo! Finance
Food and Drug Administration on Thursday voted in favor of Geron's blood disorder drug, stating that, based on late-stage trial data, the benefits outweigh treatment associated risks in patients. Among the 14 panel members, 12 backed the benefits of imetelstat, saying it outweighs the associated safety risks of the drug, while 2 voted against its use in patients. Geron is seeking approval to use imetelstat for treating transfusion-dependent anemia in patients with a group of blood cancers called myelodysplastic syndromes (MDS). The FDA's advisory panel meeting followed a review from the agency's staff on Tuesday, who raised multiple safety concerns with the treatment. The regulator, which usually follows the advice of its panel but is not bound to do so, is expected to make a decision on the drug by June 16. (Reporting by Pratik Jain and Christy Santhosh in Bengaluru; Editing by Krishna Chandra Eluri)
Show less
Read more
Impact Snapshot
Event Time:
GERN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GERN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GERN alerts
High impacting Geron Corporation news events
Weekly update
A roundup of the hottest topics
GERN
News
- Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
- Geron Corporation Reports First Quarter 2024 Financial Results and Business HighlightsBusiness Wire
- Baird downgrades Geron to neutral, cites valuation concerns [Seeking Alpha]Seeking Alpha
- Geron Co. (NASDAQ: GERN) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $4.50 price target on the stock.MarketBeat
- Geron Co. (NASDAQ: GERN) is now covered by analysts at TD Cowen. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
GERN
Earnings
- 5/2/24 - Beat
GERN
Sec Filings
- 5/2/24 - Form 8-K
- 3/27/24 - Form ARS
- 3/27/24 - Form DEFA14A
- GERN's page on the SEC website